 VANCOUVER, British Columbia, April 21, 2022 GLOBE NEWSWIRE -- BetterLife Pharma Inc. BetterLife or the Company CSE: BETR OTCQB: BETRF FRA: NPAU, an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that an abstract on the preclinical data on anti-depressant activity of its lead compound 2-bromo-LSD BETR-001 was accepted for presentation at the upcoming Canadian Association for Neuroscience CAN Conference, being held May 12-15 in Toronto, Canada. The study, led by Dr. Vern Lewis, is part of BetterLifes collaboration with the laboratory of Dr. Argel Aguilar-Valles at Carleton Universitys Department of Neuroscience. This collaboration is also supported by the Mitacs Accelerate program. 